Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of Comprehensive Medicine, Beijing Shijingshan Hospital, Beijing, China.
Front Immunol. 2022 Apr 13;13:810539. doi: 10.3389/fimmu.2022.810539. eCollection 2022.
Immunotherapy represented by immune checkpoint inhibitors has gradually entered a new era of precision medicine. In view of the limited clinical benefits of immunotherapy in patients with digestive system cancers, as well as the side-effects and high treatment costs, development of biomarkers to predict the efficacy of immune therapy is a key imperative. In this article, we review the available evidence of the value of microsatellite mismatch repair, tumor mutation burden, specific mutated genes or pathways, PD-L1 expression, immune-related adverse reactions, blood biomarkers, and patient-related biomarkers in predicting the efficacy of immunotherapy against digestive system cancers. Establishment of dynamic personalized prediction models based on multiple biomarkers is a promising area for future research.
免疫疗法以免疫检查点抑制剂为代表，已逐渐进入精准医学的新时代。鉴于免疫疗法在消化系统癌症患者中的临床获益有限，以及副作用和高治疗费用，开发预测免疫治疗疗效的生物标志物是当务之急。本文综述了微卫星错配修复、肿瘤突变负荷、特定突变基因或通路、PD-L1 表达、免疫相关不良反应、血液生物标志物和患者相关生物标志物在预测免疫治疗消化系统癌症疗效中的应用价值。基于多种生物标志物建立动态个体化预测模型是未来研究的一个有前途的领域。
